Mersana Therapeutics, Inc.
MRSN
$0.387
-$0.013-3.25%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 29.87% | 449.41% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 29.87% | 449.41% | |||
| Cost of Revenue | 50.55% | -14.16% | |||
| Gross Profit | -168.71% | 85.25% | |||
| SG&A Expenses | -9.91% | -6.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 26.37% | -11.10% | |||
| Operating Income | -22.72% | 52.59% | |||
| Income Before Tax | -27.38% | 54.33% | |||
| Income Tax Expenses | -100.00% | -- | |||
| Earnings from Continuing Operations | -22.75% | 52.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -22.75% | 52.61% | |||
| EBIT | -22.72% | 52.59% | |||
| EBITDA | -23.52% | 53.43% | |||
| EPS Basic | -21.99% | 52.72% | |||
| Normalized Basic EPS | -26.60% | 54.48% | |||
| EPS Diluted | -21.99% | 52.72% | |||
| Normalized Diluted EPS | -26.60% | 54.48% | |||
| Average Basic Shares Outstanding | 0.68% | 0.23% | |||
| Average Diluted Shares Outstanding | 0.68% | 0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||